All In Biotech

Drug Trial Radar · NCT01120691

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Dec 2, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,224

Actual

Start

Apr 2010

Primary completion

Jul 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • QVA149Drug

    QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).

  • NVA237Drug

    NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).

  • tiotropiumDrug

    Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).

  • Salbutamol/albuterolDrug

    As needed throughout the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.Time frame: 64 weeks

Locations

342 sites in 28 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Fairhope, Alabama

  • Novartis Investigative Site

    Florence, Alabama

  • Novartis Investigative Site

    Homewood, Alabama

  • Novartis Investigative Site

    Jasper, Alabama

  • Novartis Investigative Site

    Pine Bluff, Arkansas

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Palo Alto, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Stockton, California

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Pensacola, Florida

  • Novartis Investigative Site

    Couer D'Alene, Idaho

  • Novartis Investigative Site

    Normal, Illinois

  • Novartis Investigative Site

    River Forest, Illinois

  • Novartis Investigative Site

    Florence, Kentucky

  • Novartis Investigative Site

    Louisville, Kentucky

  • Novartis Investigative Site

    Opelousas, Louisiana

  • Novartis Investigative Site

    Bangor, Maine

  • Novartis Investigative Site

    Fridley, Minnesota

  • Novartis Investigative Site

    Ozark, Missouri

  • Novartis Investigative Site

    Saint Charles, Missouri

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Missoula, Montana

  • Novartis Investigative Site

    Papillion, Nebraska

  • Novartis Investigative Site

    Henderson, Nevada

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Reno, Nevada

  • Novartis Investigative Site

    Great Neck, New York

  • Novartis Investigative Site

    Massapequa, New York

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Raleigh, North Carolina

  • Novartis Investigative Site

    Wilmington, North Carolina

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Medford, Oregon

  • Novartis Investigative Site

    Portland, Oregon

Showing 40 of 342 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.